|
Cytogenetic analysis of mouse metaphase II oocytes following in vitro exposure to the proteasome inhibitor MG-132 |
||||||||
| MG-132 (mcg/ml) |
No. cells analyzed |
No. MI oocytes (%) |
No. MII oocytes (%) |
No. premature centromere separation (%) |
No. single chromatids (%) |
No. haploid (%) |
No. hypoploid (%) |
No. hyperploid (%) |
|
|
||||||||
| Control |
130 |
13 (10.0)a |
117 (90.0) |
43 (36.8)a |
1 (0.9)a |
101 (86.3) |
16 (13.7) |
-0-a |
| 5.0 |
158 |
19 (12.0)a |
139 (88.0) |
38 (27.3) |
3 (2.2)a,b |
121 (87.1) |
18 (12.9) |
-0-a |
| 7.5 |
191 |
26 (13.6)a |
165 (86.4) |
44 (26.7) |
11 (6.7)b |
142 (86.1) |
18 (10.9) |
5 (3.0)b |
| 10.0 |
125 |
53 (42.4)b |
72 (57.6) |
13 (18.1)b |
11 (15.3)c |
62 (86.1) |
3 (4.2) |
7 (9.7)c |
|
Different superscripts among proportions in the same column indicate significant (P < 0.01) differences. | ||||||||
Mailhes et al. Cell & Chromosome 2002 1:2 doi:10.1186/1475-9268-1-2 |
||||||||